Thursday, April 27, 2017

BRIEF-Ultragenyx initiates phase 3 study of UX007 in patients with disabling movement disorders

* Ultragenyx initiates global phase 3 study of UX007 in

GLUT1 DS patients with disabling movement disorders

Source text for Eikon:

Further company coverage:

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)